Home › Companies › LYELL IMMUNOPHARMA INC. › 2023-2024

LYELL IMMUNOPHARMA INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and LYELL IMMUNOPHARMA INC.’s Form 8-K, filed June 14, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.

4Ballot items
138Asset managers
681Fund votes
June 14, 2024Meeting date

Results at a glance

Meeting of June 14, 2024: 4 items on LYELL IMMUNOPHARMA INC.’s Form 8-K, filed June 14, 2024: 4 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024

Explore LYELL IMMUNOPHARMA INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by LYELL IMMUNOPHARMA INC.

These tallies are LYELL IMMUNOPHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 14, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

LYELL IMMUNOPHARMA INC. — official shareholder meeting results, meeting held June 14, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Elizabeth Nabel, M.D.	147,841,830	--	--	16,168,964	34,804,776	90%	Not verified	—
Elect Director: Lynn Seely, M.D.	150,085,827	--	--	13,924,967	34,804,776	92%	Not verified	—
2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.	198,604,866	153,727	56,977	--	--	99.9%	Not verified	—
3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.	108,778,036	46,997,736	8,235,022	--	34,804,776	70%	Not verified	—

Source: LYELL IMMUNOPHARMA INC., Form 8-K, filed with the SEC on June 14, 2024 — read the filing on EDGAR.

How asset managers voted at the LYELL IMMUNOPHARMA INC. 2023-2024 meeting

Each item below shows how the 138 asset managers that disclosed a LYELL IMMUNOPHARMA INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Elizabeth Nabel, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%

FOR: 147,841,830WITHHELD: 16,168,964

Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Election of Class III Directors: Elizabeth Nabel, M.D.

LYELL IMMUNOPHARMA INC.’s own tally for this item (“Elect Director: Elizabeth Nabel, M.D.”): 147,841,830 for, 16,168,964 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 24,885,226 for, 6,247,119 withheld.

FORWITHHOLD

FOR: 24,885,226WITHHOLD: 6,247,119

Largest asset managers voting on “Election of Class III Directors: Elizabeth Nabel, M.D.” at LYELL IMMUNOPHARMA INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	11,065,256	0	For
T. Rowe Price	5,549,552	0	For
BlackRock	4,607,087	0	For
Fidelity	61,222	3,440,456	Withhold
MFS	0	1,469,278	Withhold
Charles Schwab	1,280,612	0	For
NORTHERN LIGHTS FUND TRUST II	801,016	0	For
QUANTITATIVE MASTER SERIES LLC	334,394	0	For
John Hancock	234,729	70,870	Mixed
Equitable	72,262	174,830	Mixed
Lincoln Financial	143,900	83,215	Mixed
Global X	221,597	0	For
Invesco	0	167,700	Withhold
Nushares ETF Trust	0	156,675	Withhold
Pacific Life	69,275	82,998	Mixed
ETF Series Solutions	0	129,875	Withhold
SEI	129,836	0	For
New York Life	0	112,211	Withhold
TARGET PORTFOLIO TRUST	87,700	0	For
American Century	0	81,594	Withhold
Bridge Builder Trust	73,626	0	For
Voya	0	58,585	Withhold
Managed Portfolio Series	47,763	0	For
ProShares	0	44,862	Withhold
ETFis Series Trust I	0	42,892	Withhold

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

2. Elect Director: Lynn Seely, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%

FOR: 150,085,827WITHHELD: 13,924,967

Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Election of Class III Directors: Lynn Seely, M.D.

LYELL IMMUNOPHARMA INC.’s own tally for this item (“Elect Director: Lynn Seely, M.D.”): 150,085,827 for, 13,924,967 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 26,842,567 for, 4,289,778 withheld.

FOR

FOR: 26,842,567WITHHOLD: 4,289,778

Largest asset managers voting on “Election of Class III Directors: Lynn Seely, M.D.” at LYELL IMMUNOPHARMA INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	11,065,256	0	For
T. Rowe Price	5,549,552	0	For
BlackRock	4,607,087	0	For
Fidelity	61,222	3,440,456	Withhold
MFS	1,469,278	0	For
Charles Schwab	1,280,612	0	For
NORTHERN LIGHTS FUND TRUST II	801,016	0	For
QUANTITATIVE MASTER SERIES LLC	334,394	0	For
John Hancock	234,729	70,870	Mixed
Equitable	247,092	0	For
Lincoln Financial	143,900	83,215	Mixed
Global X	221,597	0	For
Invesco	167,700	0	For
Nushares ETF Trust	0	156,675	Withhold
Pacific Life	152,273	0	For
ETF Series Solutions	0	129,875	Withhold
SEI	129,836	0	For
New York Life	0	112,211	Withhold
TARGET PORTFOLIO TRUST	87,700	0	For
American Century	0	81,594	Withhold
Bridge Builder Trust	73,626	0	For
Voya	58,585	0	For
Managed Portfolio Series	47,763	0	For
ProShares	0	44,862	Withhold
ETFis Series Trust I	0	42,892	Withhold

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

3. 3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the…

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 8 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%AGAINST

FOR: 108,778,036AGAINST: 46,997,736

Details: description as filed, official tally, votes by 137 asset managers

Description as filed by funds: APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

LYELL IMMUNOPHARMA INC.’s own tally for this item (“3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”): 108,778,036 for, 46,997,736 against, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 46 asset managers voting on “APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at LYELL IMMUNOPHARMA INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	0	11,065,256	Against
T. Rowe Price	0	5,549,552	Against
BlackRock	0	4,607,087	Against
Fidelity	0	3,501,678	Against
MFS	0	1,469,278	Against
Charles Schwab	0	1,280,612	Against
NORTHERN LIGHTS FUND TRUST II	0	801,016	Against
QUANTITATIVE MASTER SERIES LLC	0	334,394	Against
John Hancock	0	305,599	Against
Equitable	0	247,092	Against
Lincoln Financial	143,900	83,215	Mixed
Global X	0	221,597	Against
Invesco	0	167,700	Against
Nushares ETF Trust	0	156,675	Against
Pacific Life	0	152,273	Against
ETF Series Solutions	0	129,875	Against
SEI	0	129,836	Against
New York Life	0	112,211	Against
TARGET PORTFOLIO TRUST	0	87,700	Against
American Century	0	81,594	Against
Bridge Builder Trust	0	73,626	Against
Voya	0	58,585	Against
Managed Portfolio Series	0	47,763	Against
ProShares	0	44,862	Against
ETFis Series Trust I	0	42,892	Against

Fund voting reports, all 46 managers: 193,866 for, 30,938,479 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 104 asset managers voting on “APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at LYELL IMMUNOPHARMA INC., 2023-2024
Asset manager	For	Against	Vote
Foresite Capital Management IV, LLC	8,325,000	0	For
T. Rowe Price	0	6,934,977	Against
GV Management Company, L.L.C.	5,865,125	0	For
Opaleye Management Inc.	2,980,000	0	For
GEODE CAPITAL MANAGEMENT, LLC	0	2,689,472	Against
BlackRock	70,543	2,303,954	Against
Fidelity	0	2,226,201	Against
State Street	2,127,504	13,625	For
Charles Schwab	0	1,280,612	Against
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	0	1,556,226	Against
BROWN ADVISORY INC	0	1,519,807	Against
Northern Trust	1,073,295	2,402	For
ORBIMED ADVISORS LLC	0	1,012,488	Against
Invenomic Capital Management LP	0	866,958	Against
MELLON INVESTMENTS Corp	0	741,337	Against
CANADA PENSION PLAN INVESTMENT BOARD	0	588,235	Against
Clarius Group, LLC	382,764	0	For
BAILLIE GIFFORD OVERSEAS LTD	0	293,939	Against
SEI	0	262,472	Against
Vanguard	0	224,903	Against
Invesco	0	218,174	Against
AllianceBernstein	0	174,830	Against
Nuveen	0	167,744	Against
BBR PARTNERS, LLC	164,041	0	For
WASHINGTON STATE INVESTMENT BOARD	0	140,426	Against

Institutional-manager reports, all 104 managers: 21,070,627 for, 25,001,416 against, 382,764 not voted. Showing the 25 largest; see all in the interactive database.

4. 2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 198,604,866AGAINST: 153,727

Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

LYELL IMMUNOPHARMA INC.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 198,604,866 for, 153,727 against, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 31,132,345 for.

FOR

FOR: 31,132,345

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING” at LYELL IMMUNOPHARMA INC., 2023-2024
Asset manager	For	Vote
Vanguard	11,065,256	For
T. Rowe Price	5,549,552	For
BlackRock	4,607,087	For
Fidelity	3,501,678	For
MFS	1,469,278	For
Charles Schwab	1,280,612	For
NORTHERN LIGHTS FUND TRUST II	801,016	For
QUANTITATIVE MASTER SERIES LLC	334,394	For
John Hancock	305,599	For
Equitable	247,092	For
Lincoln Financial	227,115	For
Global X	221,597	For
Invesco	167,700	For
Nushares ETF Trust	156,675	For
Pacific Life	152,273	For
ETF Series Solutions	129,875	For
SEI	129,836	For
New York Life	112,211	For
TARGET PORTFOLIO TRUST	87,700	For
American Century	81,594	For
Bridge Builder Trust	73,626	For
Voya	58,585	For
Managed Portfolio Series	47,763	For
ProShares	44,862	For
ETFis Series Trust I	42,892	For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

Largest LYELL IMMUNOPHARMA INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 254,939,222 shares outstanding at the time of that meeting.

Fund voting reports: top LYELL IMMUNOPHARMA INC. shareholders by shares voted on “APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	4.34%
2	T. Rowe Price	2.18%
3	BlackRock	1.81%
4	Fidelity	1.37%
5	MFS	0.58%
6	Charles Schwab	0.50%
7	NORTHERN LIGHTS FUND TRUST II	0.31%
8	QUANTITATIVE MASTER SERIES LLC	0.13%
9	John Hancock	0.12%
10	Equitable	0.10%

Institutional-manager reports: top LYELL IMMUNOPHARMA INC. shareholders by shares voted on “APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Foresite Capital Management IV, LLC	3.27%
2	T. Rowe Price	2.72%
3	GV Management Company, L.L.C.	2.30%
4	Opaleye Management Inc.	1.17%
5	GEODE CAPITAL MANAGEMENT, LLC	1.05%
6	BlackRock	0.93%
7	Fidelity	0.87%
8	State Street	0.84%
9	Charles Schwab	0.65%
10	MASSACHUSETTS FINANCIAL SERVICES CO /MA/	0.61%

Reported LYELL IMMUNOPHARMA INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

LYELL IMMUNOPHARMA INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Robert Nelsen	14.31%	DEF14A
Entities affiliated with ARCH Venture Partners	14.28%	DEF14A
Glaxo Group Limited	11.87%	DEF14A
Milky Way Investments Group Limited	7.91%	DEF14A
Gemini Investments, L.P.	5.92%	DEF14A
BlackRock, Inc.	5.61%	DEF14A
The Vanguard Group	5.34%	13G
Richard D. Klausner, M.D.	4.71%	DEF14A
T. Rowe Price	2.64%	13F
Hans Bishop	1.87%	DEF14A

Percentages above are of 254,939,222 shares outstanding, as reported by LYELL IMMUNOPHARMA INC. on its Form 10-Q dated May 2, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LYELL IMMUNOPHARMA INC.’s 10-Q dated May 2, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At LYELL IMMUNOPHARMA INC.'s shareholder meeting held June 14, 2024, in the 2023-2024 proxy season, 138 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 681 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — FOR was 70% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: LYELL IMMUNOPHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 14, 2024.

LYELL IMMUNOPHARMA INC. proxy season coverage: 2023-2024 (this page).

Download data (CSV): ballot items · votes by manager · column guide.